Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 467 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Background therapy Clear all
Terminated Phase 2 Interventional Results available

CD40L Antagonism in Rheumatoid Arthritis (RA)

NCT05306353
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

NCT01266902
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Rilpivirine
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
29
States / cities
Beverly Hills, California • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

NCT00819091
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 1356, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • National City, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)

NCT00891020
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
227
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

NCT03747939
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Apremilast (CC-10004), Apremilast (CC-10004) Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Mesa, Arizona • Covina, California • Encino, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

NCT03285594
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431
View directory record Official record
Conditions
Uveitis
Interventions
Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab)
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 18, 2026, 5:15 AM EDT
Enrolling by invitation Not applicable Interventional

The BEET Diabetes Feasibility Trial

NCT06247514
View directory record Official record
Conditions
Disordered Eating Behaviors
Interventions
The BEET Diabetes Program, Cognitive Behavioral Therapy Guided Self-Help
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

NCT02988115
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions
bempedoic acid, placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

NCT05007106
View directory record Official record
Conditions
Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
Interventions
Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib, 5-Fluorouracil, Cisplatin, Paclitaxel, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
14
States / cities
Anchorage, Alaska • Duarte, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 18, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

Enhanced Coordinated Specialty Care for Early Psychosis

NCT06071858
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder, Psychosis Nos/Other, Bipolar Disorder
Interventions
Care Coordination, Individual Peer Support, Digital Outreach, Cognitive Remediation, Multi-Family Group Therapy
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
Not listed
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Belmont, Massachusetts • Boston, Massachusetts • Cambridge, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 18, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

NCT04053543
View directory record Official record
Conditions
PAH
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 18, 2026, 5:15 AM EDT
Completed No phase listed Observational

Cultural Differences in Treatment Preferences and Perceptions of Acne

NCT03192163
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Survey
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 18, 2026, 5:15 AM EDT
Terminated Phase 2Phase 3 Interventional

Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

NCT00612898
View directory record Official record
Conditions
HIV Infections
Interventions
apricitabine, lamivudine
Drug
Lead sponsor
Avexa
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT01670565
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Mycophenolate Mofetil, Placebo Infusion
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 2Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

NCT05523167
View directory record Official record
Conditions
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions
EFG PH20 SC, PBO
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Alogliptin Pediatric Study

NCT02856113
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin Benzoate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
10 Years to 17 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
34
States / cities
Little Rock, Arkansas • Los Angeles, California • Palmdale, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis

NCT04706741
View directory record Official record
Conditions
Uveitis
Interventions
Izokibep, Prednisone/Prednisolone
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • Hagerstown, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 18, 2026, 5:15 AM EDT
Active, not recruiting Phase 3 Interventional

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

NCT04136353
View directory record Official record
Conditions
Prostate Cancer
Interventions
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
Drug · Radiation
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
19
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Burlington, Massachusetts + 15 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

NCT05103332
View directory record Official record
Conditions
Hypertension
Interventions
Indapamide, Amlodipine, Olmesartan, Placebo, Zilebesiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
74
States / cities
Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT03720470
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
60
States / cities
Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 18, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of SNF472 for Calciphylaxis

NCT04195906
View directory record Official record
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy
Interventions
Experimental: SNF472, Placebo Comparator: Placebo, Experimatenl SNF472 (Open-label)
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • El Centro, California • Escondido, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 18, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional Results available

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

NCT04963270
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Satralizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • Pasadena, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 18, 2026, 5:15 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 5:15 AM EDT